Popular Trials
PPAR agonist
Elafibranor for Primary Sclerosing Cholangitis
Recruiting0 awardsPhase 2
Lancaster, California
This trial is testing elafibranor, a medication, in people with Primary Sclerosing Cholangitis (PSC), a rare liver disease. PSC causes bile ducts to get damaged, leading to more liver problems. The study will evaluate if elafibranor is safe and effective in reducing liver inflammation and improving bile flow.
Monoclonal Antibodies
Combination Therapy for Crohn's Disease
Recruiting0 awardsPhase 2
Seattle, Washington
This trial is testing a new medication called JNJ-78934804 to see if it works better than two existing treatments for autoimmune conditions. The study will compare their effectiveness over several months.
Procedure
CYR-064 for Loss of Smell
Recruiting0 awardsPhase 2
Colorado Springs, Colorado
This trial is testing a new treatment called CYR-064 to see if it is safe and works well. About 150 people will take part in the study. The trial will last several months, including initial checks, treatment, and follow-up periods.
Procedure
RTA 901 for Diabetic Neuropathy
Recruiting0 awardsPhase 2
Phoenix, Arizona
This trial is testing a new drug called RTA 901 to see if it can help people with nerve pain caused by diabetes. The drug likely works by calming down the nerves that are causing the pain. The study will compare different doses of the drug to find out which dose works best.
Monoclonal Antibodies
Barzolvolimab for Eosinophilic Esophagitis
Recruiting0 awardsPhase 2
Jacksonville, Florida
This trial is testing a medication called barzolvolimab. It aims to help adult patients with Eosinophilic Esophagitis, a condition affecting the esophagus. The study will check if barzolvolimab can reduce inflammation and improve symptoms.
Popular Filters
Trials for Alzheimer's Disease Patients
ABBV-916 for Early Alzheimer's Disease
Recruiting0 awardsPhase 2
Phoenix, Arizona
This trial is testing a new drug called ABBV-916 to see if it can help people aged 50-90 who are in the early stages of Alzheimer's disease. Participants will receive the drug regularly over several months. The study aims to find out if the drug is safe and effective by monitoring changes in symptoms and side effects.
Kinase Inhibitor
Neflamapimod for Lewy Body Dementia
Recruiting0 awardsPhase 2
Lake Worth, Florida
This trial is testing neflamapimod, a drug that may help improve thinking and memory skills. It targets people with Dementia with Lewy Bodies (DLB), who often struggle with these issues. The drug works by reducing inflammation in the brain.
Oral ABBV-552 for Alzheimer's Disease
Recruiting0 awardsPhase 2
Irvine, California
This trial tests a new drug called ABBV-552 to see if it can help people aged 50-90 with early Alzheimer's disease. Participants will take the drug daily for a few months, and researchers will check its effects on memory and other symptoms.
NMDA receptor antagonist
AXS-05 for Alzheimer's Disease Agitation
Recruiting1 awardPhase 3
Toms River, New Jersey
This trial is testing a new medication called AXS-05 to see if it can help reduce agitation in people with Alzheimer's disease. The goal is to find out if AXS-05 can balance brain chemicals to calm agitation and improve behavior. AXS-05, a combination of dextromethorphan and bupropion, is being investigated for its potential to treat agitation in Alzheimer's disease and has shown promise in early clinical trials.
Behavioural Intervention
KarXT for Alzheimer's-Related Psychosis
Recruiting1 awardPhase 3
Chandler, Arizona
This trial is testing KarXT, a medication for adults aged 55-90 with Alzheimer's Disease and severe psychosis. The goal is to see if KarXT can reduce symptoms like hallucinations and delusions by balancing brain chemicals.
Phase 3 Trials
Aticaprant for Depression
Recruiting1 awardPhase 3
Colorado Springs, Colorado
This trial is testing aticaprant to see if it can help adults with major depressive disorder and anhedonia who haven't responded well to other antidepressants. Aticaprant works by blocking certain receptors in the brain to potentially improve depressive symptoms.
Behavioural Intervention
LYR-210 for Chronic Sinusitis
Recruiting1 awardPhase 3
Tucson, Arizona
This trial is designed to compare the efficacy of two treatments by randomly assigning patients to receive either one or the other. The trial will be conducted at multiple centers, will involve at least three phases, will be blinded (meaning that the patients will not know which treatment they are receiving), and will be controlled (meaning that there will be a control group of patients who receive no treatment).
Procedure
TG-C for Osteoarthritis of the Knee
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial tests TG-C, an injection into the knee, for patients with moderate to severe osteoarthritis. It aims to reduce pain and improve knee function by potentially modifying the disease. TG-C has shown promise in previous studies for managing knee osteoarthritis.
Growth Factor
Efruxifermin for NASH
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing a medication called efruxifermin (EFX) to see if it can help people with specific liver conditions. These conditions are hard to treat with current methods. EFX aims to improve liver health by reducing inflammation and fat buildup in the liver.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.